Roth Capital Affirms Buy Rating On Durata Therapeutics, Raises PT To $28
In a research report released today, Roth Capital analyst Ed Arce raised his price target on Durata Therapeutics (DRTX) to $28 (from $24), while maintaining a Buy rating on the stock. The new price target represents a potential upside of 60% from the current share price.
Arce noted, “Durata recently set the price of a course of Dalvance treatment at $4,470, well above our prior assumption of $2,950. We update our model and now project US peak sales in 2023 of nearly $850M from treating about 175,000 patients, representing, we believe, a modest ABSSSI market penetration rate of 6.2%”.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Ed Arce currently has a one-year average return of 67.3% and a 73% success rate. Arce is ranked #100 out of 3141 analysts.